102 completed, 10 recruiting, 8 unknown, 7 active not recruiting. 140 Phase 3, 11 Phase 2.
Follow tocilizumab: new trials by email Literature Review of tocilizumab trials Research Report on tocilizumab
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Test Obrixtamig Treatment in People With Different Types of Advanced Cancer Who Took Part in a Previous Study With Obrixtamig Obrixtamig, Ezabenlimab, Atezolizumab - Advanced Cancer | Phase 3 | Not yet recruiting | Boehringer Ingelheim | 68 | 2027-03-04 | 2026-11-10 |
| A Study to Compare the Efficacy and Safety of BMS-986353 (Zolacabtagene- Autoleucel / Zola-cel), CD19-CAR T Cells, Versus Standard of Care in Participants With Active Systemic Sclerosis BMS-986353, Fludarabine, Cyclophosphamide - Systemic Sclerosis | Phase 3 | Not yet recruiting | Juno Therapeutics, Inc., a Bristol-Myers Squibb Company | 92 | 2027-02-03 | 2026-09-18 |
| COMparison Between Anakinra and Tocilizumab in NORSE - "COMBAT-NORSE" Anakinra, Tocilizumab, Standard medical treatment - New Onset Refractory Status Epilepticus, New-Onset Refractory Status Epilepticus | Phase 3 | Not yet recruiting | Yale University | 438 | 2026-12-01 | 2026-08-19 |
| Infarct Growth After Intravenous Tocilizumab in Adults With Acute Ischemic Stroke Undergoing Endovascular Thrombectomy - ILLUMINATE Tociliuzumab, Placebo - Acute Ischemic Stroke | Phase 2 / Phase 3 | Not yet recruiting | Oslo University Hospital | 156 | 2026-09-21 | 2026-10-13 |
| A Clinical Trial of MK-1045 in People With B-cell Acute Lymphoblastic Leukemia (MK-1045-005) MK-1045, Blinatumomab, Acetaminophen - B-cell Acute Lymphoblastic Leukemia | Phase 2 / Phase 3 | Recruiting | Merck Sharp & Dohme LLC | 340 | 2026-05-18 | 2026-11-10 |
| Efficacy and Safety of Interleukin-6 Receptor Inhibitor Combined With Endovascular Treatment in Patients With Acute Posterior Circulation Large Vessel Occlusion Stroke Tocilizumab, Placebo - Ischemic Stroke | Phase 3 | Recruiting | Capital Medical University | 348 | 2026-04-22 | 2026-11-03 |
| Trial of Sequential Medications AfteR TNFi Failure in Juvenile Idiopathic Arthritis TNFi (Tumor Necrosis Factor inhibitor) medication, Abatacept, Tocilizumab - Polyarticular Course Juvenile Idiopathic Arthritis (JIA) | Phase 3 | Recruiting | Duke University | 400 | 2026-01-09 | 2026-10-21 |
| Efficacy and Safety of Interleukin-6 Receptor Inhibitor Combined With Endovascular Treatment in Patients With Acute Anterior Circulation Large Vessel Occlusion Stroke -2 Tocilizumab, Placebo - Acute Ischemic Stroke | Phase 3 | Active not recruiting | Capital Medical University | 692 | 2025-12-05 | 2026-10-06 |
| Interleukin-6 Receptor Inhibition for Symptomatic Intracranial Atherosclerosis Tocilizumab, NaCl 0.9% 100ml - Brain Diseases, Ischemic Stroke | Phase 3 | Not yet recruiting | Zhujiang Hospital | 486 | 2025-10-30 | 2025-07-28 |
| Efficacy and Safety of Tocilizumab for Acute Chest Syndrome Treatment in Patients With Sickle Cell Disease Tocilizumab (RoActemra®, 20 mg/mL)., Placebo (NaCl 0.9%) - Sickle Cell Disease, Acute Chest Syndrome | Phase 3 | Recruiting | Assistance Publique - Hôpitaux de Paris | 130 | 2025-08-27 | 2026-06-24 |
| Study of the Efficacy of Nintedanib+Tocilizumab in Patients With Systemic Sclerosis and Interstitial Lung Disease Tocilizumab, Nintedanib, Standard therapy - Systemic Sclerosis, Interstitial Lung Disease | Phase 3 | Recruiting | National Institute of Geriatrics, Rheumatology and Rehabilitation, Poland | 86 | 2025-07-01 | 2026-04-08 |
| Study of Salvage Therapy to Treat Patients With Granulomatosis With Polyangiitis Rituximab, Tocilizumab, Tofacitinib - Granulomatosis With Polyangiitis, Anti-neutrophil Cytoplasmic Antibody-associated Vasculitis | Phase 3 | Recruiting | Assistance Publique - Hôpitaux de Paris | 42 | 2025-06-06 | 2026-04-03 |
| Safety and Efficacy of Tocilizumab in Patients With Myelin Oligodendrocyte Glycoprotein Antibody-associated Disease Tocilizumab, Prednisone - Myelin Oligodendrocyte Glycoprotein Antibody-associated Disease | Phase 2 / Phase 3 | Active not recruiting | Tianjin Medical University General Hospital | 102 | 2024-07-09 | 2026-01-08 |
| Effect of Interleukin-6 Receptor Inhibition in Patients With Ischemic Stroke Undergoing Endovascular Treatment Tocilizumab, NaCl 0.9% 100ml - Interleukin-6, Ischemic Stroke | Phase 2 / Phase 3 | Completed | Suzhou Municipal Hospital of Anhui Province | 108 | 2024-02-02 | 2024-09-25 |
| A Study to Evaluate Glofitamab as a Single Agent vs. Investigator's Choice in Participants With Relapsed/Refractory Mantle Cell Lymphoma Obinutuzumab, Glofitamab, Rituximab - Lymphoma | Phase 3 | Recruiting | Hoffmann-La Roche | 182 | 2023-10-22 | 2026-11-05 |
| Study of Oral Upadacitinib and Subcutaneous/Intravenous Tocilizumab to Evaluate Change in Disease Activity, Adverse Events and How Drug Moves Through the Body of Pediatric and Adolescent Participants With Active Systemic Juvenile Idiopathic Arthritis. Upadacitinib, Tocilizumab - Juvenile Idiopathic Arthritis | Phase 3 | Recruiting | AbbVie | 90 | 2023-10-02 | 2026-09-15 |
| Open-Label Extension of Tocilizumab in Subjects With Generalized Myasthenia Gravis Tocilizumab Injection - Myasthenia Gravis, Generalized | Phase 2 / Phase 3 | Unknown | Tang-Du Hospital | 64 | 2023-04-01 | 2024-01-22 |
| Comparison of Complarate® (Tocilizumab Biosimilar) and Actemra® in Patients With Rheumatoid Arthritis Complarate®, Actemra® - Rheumatoid Arthritis | Phase 3 | Completed | AO GENERIUM | 465 | 2023-02-13 | 2024-07-03 |
| A Study to Evaluate Usability of Subcutaneous Auto-injector of CT-P47 in Patients With Active Rheumatoid Arthritis CT-P47 AI (tocilizumab), CT-P47 PFS (tocilizumab) - Rheumatoid Arthritis | Phase 3 | Unknown | Celltrion | 30 | 2023-02-06 | 2023-02-16 |
| A Study Evaluating Efficacy and Safety of Mosunetuzumab in Combination With Polatuzumab Vedotin Compared to Rituximab in Combination With Gemcitabine Plus Oxaliplatin in Participants With Relapsed or Refractory Aggressive B-Cell Non-Hodgkin's Lymphoma Mosunetuzumab, Polatuzumab vedotin, Tocilizumab - Non-Hodgkin Lymphoma | Phase 3 | Active not recruiting | Hoffmann-La Roche | 208 | 2022-04-25 | 2026-11-03 |
Showing 20 of 140. Sign in to see all of them.
Arthritis, Rheumatoid (73) · Arthritis, Juvenile (14) · COVID-19 (12) · Ischemic Stroke (5) · Scleroderma, Systemic (4) · Giant Cell Arteritis (3) · Stroke (3) · Community-Acquired Pneumonia (2) · Lung Diseases, Interstitial (2) · Pneumonia (2) · Polymyalgia Rheumatica (2) · Spondylitis, Ankylosing (2) · Acute Chest Syndrome (1) · Acute Lung Injury (1) · Anemia, Sickle Cell (1)
Hoffmann-La Roche (74) · Chugai Pharmaceutical (10) · Assistance Publique - Hôpitaux de Paris (6) · Capital Medical University (2) · Genentech, Inc. (2) · JW Pharmaceutical (2) · M Abdur Rahim Medical College and Hospital (2) · Oslo University Hospital (2) · Tianjin Medical University General Hospital (2) · AO GENERIUM (1) · AbbVie (1) · Abderrahmane Mami Hospital (1) · Assistance Publique Hopitaux De Marseille (1) · Assiut University (1) · Beneficência Portuguesa de São Paulo (1)
France (43) · United States (38) · Spain (32) · Italy (31) · Brazil (26) · Canada (26) · Germany (26) · United Kingdom (26) · Australia (21) · Mexico (20) · Poland (20) · Belgium (19) · China (19) · Netherlands (18) · Argentina (17)
Takahiro Kakehi (8) · Akter Kamal, MD, PhD (2) · Yuji Kimura (2) · Ajay K Nooka (1) · Anne Hege Aamodt (1) · Bart Lambrecht, MD, PhD (1) · Benjamin Terrier, MD, PhD (1) · Chao Zhang, M.D., Ph.D (1) · Chuanjie Wu, M.D. (1)
PMID 29244149, PMID 30649524, PMID 22491018, PMID 24429164, PMID 18358927, PMID 23765873, PMID 24634205, PMID 24786929, PMID 27909081, PMID 30824645, PMID 32508063, PMID 32912276, PMID 33294861, PMID 33394942, PMID 34473343, PMID 37489818, PMID 18358926, PMID 18625622, PMID 18821691, PMID 19297346, PMID 20039425, PMID 21360490, PMID 21949007, PMID 22397953, PMID 22562983, PMID 22753773, PMID 22972745, PMID 23252525, PMID 23305631, PMID 23322466, PMID 23945134, PMID 24161161, PMID 24473673, PMID 24834925, PMID 24942540, PMID 25169728, PMID 25504861, PMID 26037777, PMID 26056119, PMID 26511996, PMID 26787505, PMID 27087059, PMID 27156934, PMID 27236390, PMID 27287832, PMID 27564431, PMID 27744141, PMID 27747585, PMID 27889300, PMID 28389552
2009 (7), 2008 (6), 2015 (3), 2016 (3), 2023 (3), 2017 (2), 2019 (2), 2025 (2), P30CA138292 (1)